** Shares of Incyte INCY.O rise 3% to $61.33 premarket
** Drugmaker's Q1 adj. EPS of $1.16 beats estimates of $1.02 - LSEG data
** Its Q1 revenue of $1.05 bln comes above estimates of $993.1 mln
** Co expects annual sales of key drug Jakafi to be between $2.95 bln and $3 bln, up from prior range of $2.93 bln to $2.98 bln
** Up to last close, stock had fallen 13.8% YTD
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.